ArticleJournal of cardiothoracic surgery2025
Unlocking the therapeutic potential of lncRNA FENDRR in DCM: novel targets and insights via the miR-296-5p/HMGA1 axis.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epigenetic and chromatin remodeling mechanisms across cardiomyopathies: a comprehensive review.Epigenetics & chromatin · 2026Review
- MIR210HG promotes the progression of pediatric pneumonia by inducing apoptosis and inflammation through downregulating miR-195-5p and upregulating FGF2.BMC pediatrics · 2026Article
- Exosomal lncRNA FENDRR Orchestrates Immune Remodelling and Ferroptosis in the Comorbidity of Lung Cancer and Type 1 Myocardial Infarction.Human mutation · 2026Article
- Cardiovascular Dysfunction in Type 2 Diabetes: The Role of MicroRNAs.Handbook of experimental pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong non-coding RNA (lncRNA) holds considerable promise in mitigating the onset and progression of diabetic cardiomyopathy (DCM). FENDRR was selected due to its reported involvement in cardiac apoptosis and inflammatory regulation, key pathways in DCM pathogenesis. This study investigated role and underlying mechanisms of FENDRR in DCM.
methodsType 2 diabetes mellitus (T2DM) patients were included and stratified by DCM status. One group was T2DM patients without DCM (n = 49), and the other was T2DM patients with DCM (n = 47).. Clinical data from both groups were compared. qRT-PCR was utilized to quantify serum FENDRR expression, with ROC analysis assessing its diagnostic value. A DCM cell model was established using high glucose-treated H9c2 cells. Flow cytometry and ELISA assays measured apoptosis, myocardial enzyme levels, antioxidant enzyme levels, and inflammatory. Dual-luciferase assays confirmed FENDRR-miR-296-5p and miR-296-5p-HMGA1 interactions.
resultsFENDRR was upregulated in DCM patients and high glucose-treated H9c2s (AUC = 0.888). si-FENDRR mitigated apoptosis in high glucose-stimulated H9c2 cells by inhibiting Bax and promoting Bcl-2 expression. si-FENDRR reduced myocardial enzymes release and inflammatory, and restored antioxidant enzyme levels. miR-296-5p was validated as a target of FENDRR, exhibiting an expression pattern opposite to that of FENDRR. miR-296-5p knockdown negated the positive effects of si-FENDRR on cardiomyocytes. HMGA1, a target gene of miR-296-5p, was upregulated in DCM patients and high glucose environments.
conclusionsThis preliminary study uncovers the potential diagnostic value of FENDRR in DCM and explores its molecular mechanisms regulating myocardial cell injury via the miR-296-5p/HMGA1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.